NL-OMON42417WithdrawnNot Applicable
Omalizumab for Asthma with Non-detectable Sensitization to an Aeroallergen - OMANSA
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •* Initiation of omalizumab therapy as part of the medical treatment, based on the indication of severe or allergic asthma (group 1) or severe non-atopic asthma (group 2).
- •* Serum IgE levels and body weight within current dosing guidelines (Dosing and administration guidelines for XOLAIR. http://www.xolairhcp.com/xolairhcp/dosing-and-administration.html)
- •* Aged between 18 and 65 years old
- •* Written informed consent
Exclusion Criteria
- •* Clinical diagnosis other than asthma that may interfere with immunological assessments
- •* No initiation of omalizumab treatment
- •* Current or former smokers with a > 10 pack-year history
- •* Treatment of an asthma exacerbation in the 6 weeks prior study entry
- •* Other indications for omalizumab treatment such as ABPA, urticaria, severe food allergies
- •* Pregnancy or breastfeeding
- •* Participation in intervention studies
Investigators
Similar Trials
Recruiting
Phase 4
Omalizumab's dose reduction or increase in the frequency of administration in patients who suffer from allergic severe asthmaAsthma2025-520782-48-00Consorci Mar Parc De Salut De Barcelona110
Terminated
Phase 2
Effect of Anti-IgE in Non-Allergic AsthmaAsthmaNCT00162773Johns Hopkins University29
Completed
Phase 2
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic AnaphylaxisAnaphylaxisBronchospasmHypotensionAngioedemaNCT00890162National Institute of Allergy and Infectious Diseases (NIAID)16
Active, not recruiting
Phase 1
Reslizumab in patients with severe asthma who failed to respond to omalizumabSevere asthmaMedDRA version: 19.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2016-004459-65-ESRespira. Fundación Española del Pulmón (SEPAR)
Suspended
Not Applicable
Australian Mepolizumab Registry (AMR) for Severe AsthmaACTRN12618001497291Hunter New England Local Health District400